Daniel J. Blackman

Showing 1-7 of 7 articles

Interventions for valvular disease

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01024

Interventions for valvular disease

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort

Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01025

Coronary interventions

Post-procedural myocardial infarction following surgical aortic valve replacement and transcatheter aortic valve implantation

Dobson L, Musa T, Uddin A, Fairbairn T, Swoboda P, Ripley D, Garg P, Evans B, Malkin C, Blackman D, Plein S, Greenwood J

June 2, 2017 | 10.4244/EIJ-D-16-00558

Interventions for valvular disease

Impact of left ventricular function and transaortic gradient on outcomes from transcatheter aortic valve implantation: data from the UK TAVI Registry

Malkin C, Long W, Baxter P, Gale C, Wendler O, Monaghan M, Thomas M, Ludman P, De Belder M, Cunningham A, Moat N, Blackman D

February 19, 2016 | 10.4244/EIJY14M12_12

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D

May 21, 2013 | 10.4244/EIJV9I1A17

Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

Kelly D, McCann G, Blackman D, Curzen N, Dalby M, Greenwood J, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan J, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick A

February 22, 2013 | 10.4244/EIJV8I10A183

Complications of transcatheter aortic valve implantation: avoidance and management

Hildick-Smith D, Redwood S, Mullen M, Thomas M, Kovac J, Brecker S, Trivedi U, Young C, Hutchinson N, MacCarthy P, Prendergast B, De Belder M, Monaghan M, Blackman D, Baumbach A, Manoharan G, Moat N

September 30, 2011 | 10.4244/EIJV7I5A99

1

Latest news

CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR

Ahead of Print: Coronary Artery Thrombosis in COVID-19

Coronary collaterals, the natural grafts of CTO lesions

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

(The Trials book is supported by Biotronik)

Guidance Papers

Guidelines, consensus & position papers

Intravascular ultrasound in PCI for in-stent CTO: guidance for long-term success

JM De la Torre Hernandez

This Week's JAA's: Real-world Use of the Evolut PRO Valve...

Valvular disease